Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors

• Published in: Frontiers in immunology Vol. 14; p. 1094414
• Main Authors: Hu, Xiangxiao, Wang, Lina, Shang, Bin, Wang, Junren, Sun, Jian, Liang, Bin, Su, Lili, You, Wenjie, Jiang, Shujuan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.03.2023
• Subjects: Antibodies, Monoclonal - adverse effects; Carcinoma, Non-Small-Cell Lung; combined immunotherapies; Humans; immune checkpoint inhibitor; Immune Checkpoint Inhibitors - adverse effects; immune-related toxicity; Immunology; Lung Neoplasms; non-small cell lung cancer; predictive biomarker; Risk Factors; non-small cell lung cancer; immune checkpoint inhibitor; predictive biomarker; immune-related toxicity; combined immunotherapies
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1094414

Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, etc, have revolutionized cancer treatment strategies, including non-small cell lung cancer (NSCLC). While these immunotherapy agents have achieved durable clinical benefits in a subset of NSCLC patients, they bring in a variety of immune-related adverse events (irAEs), which involve cardiac, pulmonary, gastrointestinal, endocrine and dermatologic system damage, ranging from mild to life-threatening. Thus, there is an urgent need to better understand the occurrence of irAEs and predict patients who are susceptible to those toxicities. Herein, we provide a comprehensive review of what is updated about the clinical manifestations, mechanisms, predictive biomarkers and management of ICI-associated toxicity in NSCLC. In addition, this review also provides perspective directions for future research of NSCLC-related irAEs.